Abstract
Conventional treatment of pulmonary arterial hypertension (PAH) includes oxygen supplementation, calcium channel blockers, anticoagulation, digoxin, and diuretics. Calcium channel blockers have little or no effect on the majority of patients with moderate or severe PAH. Apart from the intravenous prostacyclin which remains the gold standard treatment for this life-threatening entity, newer drugs such as prostacyclin analogues, endothelin-receptor antagonists, and phosphodiesterase-5 inhibitors alone or in combination administered by means of different routes have been shown to improve oxygenation, hemodynamics, exercise tolerance, symptoms, and quality of life. Based on current WHO classification there are 5 groups of pulmonary hypertension. In this article, PAH is used exclusively for Group 1 of WHO classification. There are currently six FDA approved therapies for PAH. However, all these therapeutic agents and approaches have not offered yet a cure of PAH. This review article presents the recent advances in the management of PAH.
Keywords: Prostanoids, nitric oxide, endothelin-receptor antagonist, epoprostenol, phosphodiesterase 5 inhibitors
Current Respiratory Medicine Reviews
Title: Recent Advances in the Management of Pulmonary Arterial Hypertension
Volume: 5 Issue: 1
Author(s): Emmanuel Papadakis and Argyris Michalopoulos
Affiliation:
Keywords: Prostanoids, nitric oxide, endothelin-receptor antagonist, epoprostenol, phosphodiesterase 5 inhibitors
Abstract: Conventional treatment of pulmonary arterial hypertension (PAH) includes oxygen supplementation, calcium channel blockers, anticoagulation, digoxin, and diuretics. Calcium channel blockers have little or no effect on the majority of patients with moderate or severe PAH. Apart from the intravenous prostacyclin which remains the gold standard treatment for this life-threatening entity, newer drugs such as prostacyclin analogues, endothelin-receptor antagonists, and phosphodiesterase-5 inhibitors alone or in combination administered by means of different routes have been shown to improve oxygenation, hemodynamics, exercise tolerance, symptoms, and quality of life. Based on current WHO classification there are 5 groups of pulmonary hypertension. In this article, PAH is used exclusively for Group 1 of WHO classification. There are currently six FDA approved therapies for PAH. However, all these therapeutic agents and approaches have not offered yet a cure of PAH. This review article presents the recent advances in the management of PAH.
Export Options
About this article
Cite this article as:
Papadakis Emmanuel and Michalopoulos Argyris, Recent Advances in the Management of Pulmonary Arterial Hypertension, Current Respiratory Medicine Reviews 2009; 5 (1) . https://dx.doi.org/10.2174/157339809787353976
DOI https://dx.doi.org/10.2174/157339809787353976 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Gender Bender effect in Periodontal Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
Current Medicinal Chemistry The Role of Matrix Metalloproteinases in Essential Hypertension
Current Topics in Medicinal Chemistry Arterial Stiffness:A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Hypertension Reviews Hepatoma Derived Growth Factor is a Nuclear Targeted Mitogen
Current Drug Targets Nitric Oxide: A Key Mediator of Biofilm Dispersal with Applications in Infectious Diseases
Current Pharmaceutical Design Function and Pharmacology of Spinally-Projecting Sympathetic Pre-Autonomic Neurones in the Paraventricular Nucleus of the Hypothalamus
Current Neuropharmacology Meet Our Editorial Board Member
Current Bioactive Compounds Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions
Current Enzyme Inhibition Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions
Current Pharmaceutical Design NADPH Oxidases in the Heart
Current Cardiology Reviews The Serum Protein and Lipid Oxidation Marker Levels in Alzheimers Disease and Effects of Cholinesterase Inhibitors and Antipsychotic Drugs Therapy
Current Alzheimer Research Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Current Cardiology Reviews The Relevance of Dietary Polyphenols in Cardiovascular Protection
Current Pharmaceutical Design The Atherosclerosis Time-Line and the Role of the Endothelium
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Antenatal Maternal Antidepressants Drugs Affect S100B Concentrations in Fetal-Maternal Biological Fluids
CNS & Neurological Disorders - Drug Targets Manoyl-Oxide Biotransformations with Filamentous Fungi
Current Organic Chemistry